Table 1.
Citrullinated CK‐13 peptides identified in GCF from healthy controls, patients with both PD and RA, patients with PD only, and patients with RA onlya
| Citrullinated CK‐13 peptide | Control (n = 2) | PD and RA (n = 3) | PD (n = 2) | RA (n = 1) |
|---|---|---|---|---|
| 5LQSSSASYGGGFGGGSCQLGGG(cit)GVSTCSTR35 b | 1 | 0 | 0 | 0 |
| 326RTLQGLEIELQSQLSMKAGLENTVAETEC(cit)355 c | 1 | 0 | 0 | 0 |
| 407SLLEGQDAKMIGFPSSAGSVSP(cit)R430 b | 1 | 0 | 0 | 0 |
| 430STSVTTTSSASVTTTSNASG(cit)R451 b, c | 1 | 1 | 2 | 0 |
| 451(cit)TSDV(cit)RP458 b, c | 1 | 2 | 1 | 0 |
| 451(cit)TSDVR(cit)P458 b, c | 1 | 2 | 1 | 0 |
| 452TSDV(cit)RP458 c | 1 | 1 | 1 | 1 |
| 452TSDVR(cit)P458 c | 1 | 1 | 0 | 0 |
a
Values are the number of patients. CK‐13 = cytokeratin 13; PD = periodontitis; RA = rheumatoid arthritis.
b
Gingival crevicular fluid (GCF) with no tryptic digest.
c
Tryptic digest of GCF solution.